
A new report from Americans for Tax Fairness concludes:
“In addition to dodging its fair share of taxes, Pfizer—maker of Celebrex, Lipitor, Lyrica, and Viagra, among many other health-care products—has also been aggressively raising prescription drug prices, thereby straining patients and our health care system and in some cases putting needed medications out of reach.
By dodging taxes while boosting prescription drug prices, Pfizer squeezes American families and communities from two sides at once. In the company’s biggest insult to America yet, Pfizer’s merger will allow it to go on enjoying all the benefits of being based here—everything from a publicly educated workforce to an excellent communications infrastructure to a reliable patent system—without adequately paying to support them.”
The two wealth-extracting techniques go together, very often. This is what modern capitalism is increasingly becoming.
Why doesn’t Pfizer’s leadership focus on what it was originally set up to do: wealth creation? And don’t get us started on shareholder value.
Related articles

UN tax convention hub – updates & resources

UN Framework Convention – Roundup of the Fifth Session of Negotiations
Notes on the UN tax convention draft protocol on dispute prevention and resolution
11 September 2026

The European Court of Justice strikes against transparency again. Our response should be to call for an end to corporate limited liability
Report of the Fifth Session of negotiations on the UN tax convention
4 September 2026
Submission to Workstream I on Co-Lead’s Zero Draft of UN Framework Convention on International Tax Cooperation (post-Fifth Session)
28 August 2026
Submission to Workstream II on Taxation of Income from Cross-Border Services (post-Fifth Session)
26 August 2026
Strengthening public resource mobilization through tax justice
25 August 2026
Submission to Workstream III on Dispute Prevention and Resolution (post-Fifth Session)
24 August 2026

From data to policy: Building Africa’s evidence ecosystem for better tax reform
